Ainos Inc (AIMD)

Mar 24, 2025, 5:00 PM EDT - 9 days ago

Ainos to Participate in Fireside Chat with Water Tower Research on April 8, 2025

Mar 13, 2025, 9:00 AM EDT - 20 days ago

Water Tower Research Spotlights Ainos & ASE Partnership: Unleashing AI Nose's Potential in Chip Manufacturing and More

ASX

Mar 11, 2025, 9:00 AM EDT - 22 days ago

Ainos and ASE Partner to Power AI Scent Digitization in Semiconductor Manufacturing

ASX

Mar 7, 2025, 4:45 PM EST - 26 days ago

Ainos Reports Full Year 2024 Financial Results

Mar 7, 2025, 1:30 PM EST - 26 days ago

Water Tower Research Highlights Ainos & ugo Partnership: The Final Sense for Robots - AI Smell is Here

Mar 5, 2025, 10:00 AM EST - 4 weeks ago

Ainos and ugo to Develop the World's First Robot With a Sense of Smell

Jan 27, 2025, 10:00 AM EST - 2 months ago

Ainos Achieves Major Breakthrough: Japan Patent Approval for VELDONA Redefines Antiviral Innovation

Jan 21, 2025, 10:00 AM EST - 2 months ago

Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025

Jan 17, 2025, 9:00 AM EST - 2 months ago

Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule

Jan 13, 2025, 10:00 AM EST - 2 months ago

Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

Dec 18, 2024, 12:05 PM EST - 3 months ago

CORRECTION BY SOURCE: Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

Dec 18, 2024, 8:00 AM EST - 3 months ago

Smell the Future: Ainos Elevates Health and Technology With AI Nose and VELDONA

Dec 13, 2024, 8:00 AM EST - 3 months ago

Ainos Joins Webull Corporate Connect Service Platform to Enhance Investor Engagement

Dec 4, 2024, 8:00 AM EST - 4 months ago

Water Tower Research Underscores Ainos' Partnership With Taiwan Tanabe Seiyaku for VELDONA Manufacturing and Marketing

Dec 2, 2024, 8:00 AM EST - 4 months ago

Ainos, Inc. Announces Strategic Partnership with Taiwan Tanabe Seiyaku to Advance Manufacturing and Taiwan Market Promotion of Sjögren's Syndrome Drug

Nov 13, 2024, 8:00 AM EST - 5 months ago

Water Tower Research Highlights IRB Approval for the Ainos VELDONA Clinical Sjogren's Trial Alongside 3Q24 Earnings and Developments

Nov 11, 2024, 8:00 AM EST - 5 months ago

Ainos Announces IRB Approval for Sjögren's Syndrome Clinical Study at Shuang Ho Hospital, Affiliated with Taipei Medical University, and Plans to Initiate New Phase of Treatment Evaluation in Q1 2025

Nov 8, 2024, 8:00 AM EST - 5 months ago

Ainos Takes Decisive Action to Protect Stockholder Interests and Combat Potential Illegal Trading Activities

Nov 6, 2024, 4:30 PM EST - 5 months ago

Ainos Reports Third Quarter 2024 Financial Results

Oct 28, 2024, 8:00 AM EDT - 5 months ago

Ainos Expands Patent Portfolio With Strategic Shareholder's Cutting-Edge Technology Assets

Oct 24, 2024, 10:50 AM EDT - 5 months ago

Ainos Highlights VELDONA Clinical Advancements and Market Potential in Water Tower Research Spotlight Podcast

Oct 7, 2024, 8:00 AM EDT - 6 months ago

Ainos Advances Healthcare and Industrial Innovations with AI Nose and VELDONA Technologies

Sep 25, 2024, 8:00 AM EDT - 6 months ago

Ainos, Inc. Receives IRB Approval From National Taiwan University Hospital for HIV-Oral Warts Clinical Trial, Highlighting Value of FDA-Designated Orphan Drug VELDONA

Sep 24, 2024, 10:55 AM EDT - 6 months ago

Ainos Spotlighted in Water Tower Research Report on VELDONA Clinical Study for Sjogren's Syndrome

Sep 23, 2024, 8:00 AM EDT - 6 months ago

Ainos Announced Plan to Initiate Taiwan Clinical Study of VELDONA for Treating Sjögren's Syndrome, a Rare Disease With Limited Treatment Options

Sep 20, 2024, 8:00 AM EDT - 6 months ago

Water Tower Research Highlights Ainos VELDONA Clinical Trial for HIV+ Patients with Oral Warts

Sep 17, 2024, 8:00 AM EDT - 7 months ago

Ainos Announced Plan to Initiate Taiwan Clinical Study for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Sep 3, 2024, 8:30 AM EDT - 7 months ago

Ainos Secures Taiwan Invention Patent and Advances Global Patent Protection for VELDONA, a Breakthrough in Coronavirus Treatment and Prevention

Aug 27, 2024, 8:30 AM EDT - 7 months ago

Ainos to Participate in H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 8:30 AM EDT - 7 months ago

Ainos CEO Highlights AI Nose Achievements and Upcoming 2H 2024 Milestones in Shareholder Letter

Aug 19, 2024, 9:15 AM EDT - 8 months ago

Ainos Unveils AI Nose Breakthrough that Revolutionizes Smart Manufacturing Factory Automation and Manufacturing Safety

Aug 12, 2024, 8:00 AM EDT - 8 months ago

Ainos to Participate in Fireside Chat with Water Tower Research on August 22, 2024

Aug 9, 2024, 4:15 PM EDT - 8 months ago

Ainos Secures Exclusive Multi-Regions Invention Patent Licenses from Strategic Partner to Bolster AI Nose and Point-Of-Care Testing

Aug 6, 2024, 7:30 AM EDT - 8 months ago

Ainos Concludes Growth Financing From Lind Partners

Aug 5, 2024, 4:15 PM EDT - 8 months ago

Ainos Reports Second Quarter 2024 Financial Results

Jul 23, 2024, 8:30 AM EDT - 9 months ago

Ainos Enrolls First Subject for Clinical Study of VELDONA-Based Animal FCGS Drug

Jun 14, 2024, 8:00 AM EDT - 10 months ago

Ainos Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA

May 15, 2024, 8:00 AM EDT - 11 months ago

Ainos to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market

May 13, 2024, 4:10 PM EDT - 11 months ago

Ainos Reports First Quarter 2024 Financial Results

May 7, 2024, 8:00 AM EDT - 11 months ago

Ainos Raises $9 Million in Growth Capital with Existing Shareholder

Mar 8, 2024, 4:20 PM EST - 1 year ago

Ainos Reports Full Year 2023 Financial Results

Feb 5, 2024, 9:00 AM EST - 1 year ago

Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms

Jan 24, 2024, 9:00 AM EST - 1 year ago

Ainos Announces $1.75 Million Follow-On Funding

Jan 2, 2024, 9:00 AM EST - 1 year ago

Ainos Regains Compliance with Nasdaq Minimum Bid Price Requirement

Dec 26, 2023, 9:00 AM EST - 1 year ago

Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-development Powered by AI Nose, Accelerating the Digitalization of Smell

Dec 12, 2023, 8:00 AM EST - 1 year ago

Ainos, Inc. Announces Stock Consolidation

Nov 28, 2023, 8:30 AM EST - 1 year ago

Ainos Announces Successful Manufacturing of VELDONA GMP Clinical Batch by Swiss Pharmaceutical

Nov 21, 2023, 8:30 AM EST - 1 year ago

Ainos Announces Positive Data Reported from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA

Nov 9, 2023, 4:30 PM EST - 1 year ago

Ainos Reports Third Quarter 2023 Financial Results

Nov 6, 2023, 8:00 AM EST - 1 year ago

Ainos Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on VELDONA